Evidence map›Paper›PMID 39947641›Full record

ArticleEndoscopy2025

Outcomes after radical endoscopic resection of high risk T1 esophageal adenocarcinoma: an international multicenter retrospective cohort study.

Man Wai Chan, Rehan Haidry, Benjamin Norton, Massimiliano di Pietro, Andreas V Hadjinicolaou, Maximilien Barret, Paul Doumbe Mandengue, Stefan Seewald, Raf Bisschops, Philippe Nafteux and 11 more

Abstract readMulticenter Study
In one paragraph

Article in Endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Man Wai ChanGastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, Netherlands.
Rehan HaidryDivision of Gastroenterology and Hepatology, University College London, London, United Kingdom of Great Britain and Northern Ireland.
Benjamin NortonDivision of Gastroenterology and Hepatology, University College London, London, United Kingdom of Great Britain and Northern Ireland.ORCID 0000-0003-2058-3162
Massimiliano di PietroDivision of Gastroenterology and Hepatology, Department of Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom of Great Britain and Northern Ireland.
Andreas V HadjinicolaouDivision of Gastroenterology and Hepatology, Department of Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom of Great Britain and Northern Ireland.
Maximilien BarretGastroenterology and Digestive Oncology, Hôpital Cochin, Paris, France.
Paul Doumbe MandengueGastroenterology and Digestive Oncology, Hôpital Cochin, Paris, France.ORCID 0000-0003-4597-5058
Stefan SeewaldCenter for Gastroenterology, Hirslanden Clinic, Zurich, Switzerland.
Raf BisschopsGastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-9994-8226
Philippe NafteuxThoracic Surgery, University Hospitals Leuven, Leuven, Belgium.
Michael J BourkeGastroenterology and Hepatology, Westmead Hospital, Sydney, Australia.
Sunil GuptaGastroenterology and Hepatology, Westmead Hospital, Sydney, Australia.ORCID 0000-0003-3471-8304
Pradeep MundreGastroenterology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom of Great Britain and Northern Ireland.
Arnaud LemmersGastroenterology, Hepatopancreatology and Digestive Oncology, Hopital Erasme, Brussels, Belgium.
Clémence VuckovicGastroenterology, Hepatopancreatology and Digestive Oncology, Hopital Erasme, Brussels, Belgium.
Oliver PechGastroenterology, Regensburg Hospital of the Hospitaller Order of the Brothers of Saint John of God, Regensburg, Germany.
Philippe LeclercqGastroenterology, Clinique CHC Mont Légia, Liège, Belgium.
Emmanuel CoronEndoscopy and Gastroenterology, CHU Nantes, Nantes, France.
Sybren L MeijerHistopathology, Amsterdam University Medical Centres, Amsterdam, Netherlands.ORCID 0000-0002-6953-2406
Jacques J G H M BergmanGastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, Netherlands.ORCID 0000-0001-7548-6955
Roos E PouwGastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Post-endoscopic resection (ER) management of high risk T1 esophageal adenocarcinoma (EAC) is debated, with conflicting reports on lymph node metastasis (LNM). We aimed to assess outcomes following radical ER for high risk T1 EAC. Methods: We identified patients who underwent radical ER (tumor-negative deep margin) of high risk T1 EAC, followed by surgery or endoscopic surveillance, between 2008 and 2019 across 11 international centers. Results: 106 patients (86 men; mean [SD] age, 70 [11] years) were included. Of these, 26 (age, 64 [11] years) underwent additional surgery, with residual T1 EAC found in five patients (19%) and LNM in two (8%). After a median [IQR] follow-up of 47 [32–79] months, 2/26 patients (8%) developed LNM/distant metastasis, with one EAC-related death (4%), one unrelated death (4%), and four patients lost to follow-up (15%). Of the 80 patients (age, 71 [9] years) who entered endoscopic surveillance, 5/80 (6%) developed LNM/distant metastasis, with four EAC-related deaths (5%) over 46 (IQR 25–59) months follow-up; there were 15 unrelated deaths (19%), and 10 patients lost to follow-up (13%). The overall rates (95%CI) were: LNM, 6% (2%–12%); LNM/distant metastasis, 7% (3%–13%); EAC-related mortality, 5% (2%–11%); overall mortality, 20% (95%CI 13–29). Conclusion: Our findings present low rates of LNM after radical ER of high risk T1 EAC, consistent with other endoscopy-focused studies. Post-surgical patients are still at risk for metastasis and disease-specific mortality. These results suggest that endoscopic surveillance is suitable for selected cases, but further prospective studies are needed to refine patient selection and confirm optimal outcomes.

Indexed as

AdenocarcinomaEsophageal NeoplasmsEsophagectomyEsophagoscopyAgedFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm StagingRetrospective StudiesTreatment Outcome

Identifiers

PMID39947641
PMCPMC12224666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.